Technology Appraisal Committee Meeting (CDF Committee)

Minutes: Confirmed

Date and Time: Wednesday 25 May, 10:00am to 3:30pm

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present: 1. Chair Dr Jane Adam Present for all notes
          2. Dr Jeff Aronson Present for all notes
          3. Professor David Bowen Present for all notes
          4. Andrew England Present for all notes
          5. Professor Gary McVeigh Present for all notes
          6. Professor Eugene Milne Present for all notes
          7. Dr Mohit Misra Present for all notes
          8. Dr Anna O'Neill Present for all notes
          9. Christopher O'Regan Present for all notes
         10. Dr Danielle Preedy Present for all notes
         11. Professor Matt Stevenson Present for all notes
         12. David Thomson Present for all notes
         13. Dr Nicky Welton Present for all notes
         14. Dr Olivia Wu Present for all notes

In attendance:

Professor Carole Longson Director, National Institute for Health and Care Excellence Present for all notes

Meindert Boysen Programme Director, National Institute for Health and Care Excellence Present for all notes

Dr Frances Sutcliffe Associate Director, National Institute for Health and Care Excellence Present for notes 01 to 14

Helen Knight Associate Director, National Institute for Health and Care Excellence Present for notes 15 to 27

Jenna Dilkes Project Manager, National Institute for Health and Care Present for all notes
Excellence

Gavin Kenny Administrator, National Institute for Health and Care Excellence  Present for all notes

Sabine E Grimm Research Associate Health Economics and Decision Science School of Health and Related Research  Present for all notes

Tristan Snowsill ERG representative Present for notes 01 to 12

Adrian Bagust ERG representative Present for notes 15 to 23

Peter Clark NHS Commissioning Expert Present for notes 01 to 27

David Thomson NHS Commissioning Expert Present for notes 01 to 12

Dr Jennifer Byrne Clinical Expert Present for notes 01 to 12

Professor Adam Mead Clinical Expert Present for notes 01 to 12

Dr Yvonne Summers Clinical Expert Present for notes 15 to 23

Russell Cooper Patient Expert Present for notes 01 to 10

David Ryner Patient Expert Present for notes 01 to 12

Non-public observers:

Elizabeth Adelanwa NICE Observer Present for all notes

Andrew Bomford Radio 4 Present for notes 01 to 10

Martyn Burke NICE Observer Present for all notes

Ann Greenwood NICE Observer Present for all notes

Carl Jackson NICE Observer Present for all notes

Andrew Kenyon NICE Observer Present for all notes

Linda Landells NICE Observer Present for all notes

Edgar Masanga NICE Observer Present for all notes

Deborah Morrison NICE Observer Present for all notes

Jennifer Prescott NICE Observer Present for all notes
Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of Bosutinib for previously treated chronic myeloid leukaemia (review of TA299) and Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer (review of TA309).

Any other Business

2. none

Appraisal of Bosutinib for previously treated chronic myeloid leukaemia (review of TA299)

Part 1 – Open session

3. The Chair welcomed the invited experts: Dr Jennifer Byrne, Peter Clark, Russell Cooper, Professor Adam Mead, David Ryner, Tristan Snowsill, and David Thomson to the meeting and they introduced themselves to the Committee.

4. The Chair welcomed company representatives from Pfizer to the meeting.

5. The Chair asked all Committee members to declare any relevant interests

5.1. Dr Jane Adam, Dr Jeff Aronson, Andrew England, Professor Gary McVeigh, Professor Eugene Milne, Dr Mohit Misra, Dr Anna O'Neill, Christopher O'Regan, Dr Danielle Preedy, Professor Matt Stevenson, David Thomson, and Dr Nicky Welton, all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Bosutinib for previously treated chronic myeloid leukaemia (review of TA299).

5.2. Professor David Bowen declared a personal specific non-financial interest as he acted as the co-investigator on a clinical trial for Bosutinib. 9.2.1 It was agreed that this declaration would not prevent Professor David Bowen from participating in this section of the meeting.

5.3. Dr Olivia Wu declared a personal specific non-financial interest as she received a methodology research grant from Pfizer. 9.3.1 It was agreed that this declaration would not prevent Dr Olivia Wu from participating in this section of the meeting.

6. The Chair asked all NICE Staff to declare any relevant interests.
6.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Bosutinib for previously treated chronic myeloid leukaemia (review of TA299).

7. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

7.1. Russell Cooper, Peter Clark, David Thomson and Tristan Snowsill declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Bosutinib for previously treated chronic myeloid leukaemia (review of TA299).

7.2. Dr Jennifer Byrne declared a personal non-specific financial interest as she accepted speaking engagements from Pfizer and other Chronic Myeloid Leukaemia drug manufacturers.

7.2.1. It was agreed that this declaration would not prevent Dr Jennifer Byrne from participating in this section of the meeting.

7.3. Professor Adam Mead declared a personal non-specific financial interest as she accepted speaking engagements from Pfizer and other Chronic Myeloid Leukaemia drug manufacturers.

7.3.1. It was agreed that this declaration would not prevent Professor Adam Mead from participating in this section of the meeting.

7.4. David Ryner declared a personal non-specific financial interest as the CMLSG had received support from Pfizer.

7.4.1. It was agreed that this declaration would not prevent David Ryner from participating in this section of the meeting.

8. The Chair gave presentations on the clinical effectiveness and cost effectiveness of Bosutinib for previously treated chronic myeloid leukaemia (review of TA299).

9. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

10. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960) and all public attendees left the meeting.

Part 2a – Closed session
11. Discussion on confidential information continued. This information was supplied by the company.

12. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

**Part 2b – Closed session**

13. The Committee continued to discuss the clinical and cost effectiveness of Bosutinib for previously treated chronic myeloid leukaemia (review of TA299).

13.1. A vote was taken. The options were:
Option 1: Bosutinib for previously treated chronic myeloid leukaemia (review of TA299) is recommended for use within the NHS.
Option 2: Bosutinib for previously treated chronic myeloid leukaemia (review of TA299) is not recommended for use within the NHS.

The Committee voted for Option 1. Details of the result of this discussion will be included in the confirmed version of these minutes, which will be published during the week commencing 27 June 2016 after the publication of all decisions taken at this Committee meeting.

14. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD) in line with their decisions.

**Appraisal of Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer (review of TA309)**

**Part 1 – Open session**

15. The Chair welcomed the invited experts: Adrian Bagust, Peter Clark, David Thomson and Dr Yvonne Summers to the meeting and they introduced themselves to the Committee.

16. The Chair welcomed company representatives from Eli Lilly and Company to the meeting.

17. The Chair asked all Committee members to declare any relevant interests

17.1. Dr Jane Adam, Dr Jeff Aronson, Professor David Bowen, Andrew England, Professor Gary McVeigh, Professor Eugene Milne, Dr Mohit Misra, Dr Anna O'Neill, Christopher O'Regan, Dr Danielle Preedy, Professor Matt Stevenson, David Thomson, Dr Nicky Welton, Dr Olivia Wu all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer (review of TA309).
18. The Chair asked all NICE Staff to declare any relevant interests.

18.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer (review of TA309).

19. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

19.1. Adrian Bagust, Peter Clark, David Thomson that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer (review of TA309).

19.2. Dr Yvonne Summers declared a non-personal specific financial interest as she had participated in advisor boards for Eli Lilly and Company.  
19.2.1. It was agreed that this declaration would not prevent Dr Yvonne Summers from participating in this section of the meeting.

20. The Chair gave presentations on the clinical effectiveness and cost effectiveness of Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer (review of TA309).

21. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

22. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

23. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

24. Discussion on confidential information continued. This information was supplied by the company.

25. The Committee continued to discuss the clinical and cost effectiveness of Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer (review of TA309).
25.1. The committee decision was based on consensus.

26. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

27. Tuesday 26th July, 10:00 to 17:00 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.